tfcc tear bpc 157 BPC-157 Research Peptide | BPC-157
Description
Phase Cag introduction Weeks 9-12 Retatrutide 4 mg/week (hold) Cagrilintide 0.25 mg/week Notes Add cagrilintide at the lowest dose
Researchers first characterised the peptide in the early 1990s, and its since built up one of the most extensive bodies of preclinical literature in the field
Bai, Z., Wang, J., Li, J., Yuan, H., Wang, P., Zhang, M., Feng, Y., Cao, X., Cao, X., Kang, G., de Marco, A., & Huang, H
2008;108:c2026
